Results 211 to 220 of about 74,157 (302)

Janus Kinase Inhibitors During Pregnancy and Adverse Drug Reactions: A Pharmacovigilance Disproportionality Analysis in VigiBase. [PDF]

Clin Transl Sci
Abolhassani N, Noseda R, Dao K, Girardin FR, Bedussi F, Ceschi A, Panchaud A, Winterfeld U.   +7 more
europepmc   +1 more source

Extracellular vesicles released from melanoma cells constitutively expressing MHC class II promote immune evasion and cancer progression

The FEBS Journal, EarlyView.
Here, we report the role of extracellular vesicles (EVs) released from melanoma cells constitutively expressing MHC class II in the regulation of immune cell functions and melanoma metastasis. In particular, we observed an increased localization of HLA‐DRα, CAM receptors, PD‐L1, and STAT3 signaling proteins in the EVs.
Francesca Costantini, Caterina Di Sano, Samuele Raccosta, Mauro Manno, Giovanna Barbieri   +4 more
wiley   +1 more source

Adverse effects of Janus kinase inhibitors with relevance for daily practice in dermatology. [PDF]

J Dtsch Dermatol Ges
Rajput Khokhar A, Ghoreschi K, Huynh J.
europepmc   +1 more source

The emerging role of the Hippo signaling pathway in interorgan crosstalk

The FEBS Journal, EarlyView.
Hippo signaling functions as a central hub of interorgan communication. Systemic cues from the gut, adipose tissue, and skeletal muscle—including hormones, metabolites, and microbial signals—regulate YAP/TAZ activity in a tissue‐ and context‐dependent manner.
Gahyeon Song, Chaerin Lee, Eek‐hoon Jho   +2 more
wiley   +1 more source

Revisiting Janus Kinase Inhibitors in Hospitalized COVID-19: Evidence for Baricitinib's Superiority and the Absence of a Class Effect. [PDF]

J Inflamm Res
Gu L, Lin J, Yue J, Liu Z, Huang JA.
europepmc   +1 more source

Understanding and addressing resistance to IMiDs immunomodulatory compounds in multiple myeloma

The FEBS Journal, EarlyView.
IMiDs are pivotal in the treatment of multiple myeloma. Mechanisms of resistance comprise cell intrinsic and extrinsic pathways, involving tumour microenvironment, immune cell dysfunction, CRBN‐dependent and independent genetic drivers and epigenetic changes.
Maria‐Cynthia Fuentes‐Lacouture, Devi Nandana, Karthik Ramasamy, Anjan Thakurta   +3 more
wiley   +1 more source

Real-world experience with Janus kinase inhibitors in rheumatoid and psoriatic arthritis: retention and discontinuation factors in a UK six-centre cohort. [PDF]

Rheumatol Adv Pract
Nathan J, Farisogullari B, Jones N, Ayoub M, Brown J, Levy S, Brader J, Ersoy A, Israni B, Lloyd M, Latheef A, Hill D, Taylor A, Arachchige D, Chitsu H, Linklater H, Lather K, Gompels L, Elfar E, Malaiya R, Machado PM, Kiely PDW.   +21 more
europepmc   +1 more source

Increased Levels of Inflammatory Proteins, Including TARC/CCL17, in Skin of AD Patients During JAK Inhibitor Treatment

Clinical &Experimental Allergy, Volume 55, Issue 3, Page 260-263, March 2025.
Celeste M. Boesjes, Lian F. van der Gang, Daphne S. Bakker, C. F. den Hartog Jager, Marlies de Graaf, Marjolein S. de Bruin‐Weller, Femke van Wijk, Edward F. Knol   +7 more
wiley   +1 more source

Minimal Disease Activity as A New Therapeutic Target in Atopic Dermatitis: A 5‐Year Real‐Life Experience With Dupilumab

International Journal of Dermatology, EarlyView.
ABSTRACT Background Atopic dermatitis (AD) is a chronic inflammatory skin disease with significant physical and psychosocial burden. Dupilumab, a monoclonal antibody targeting IL‐4Rα, has proven to be effective for moderate‐to‐severe AD, but long‐term real‐world data remain limited.
Francesco Leo, Luca Mastorino, Luca Cangialosi, Davide Favre, Chiara Anna Fiasconaro, Yingying Liao, Federico Goso, Niccolò Siliquini, Giovanni Cavaliere, Pietro Quaglino, Simone Ribero, Michela Ortoncelli   +11 more
wiley   +1 more source

Janus kinase inhibitors in localized scleroderma: a systematic literature review. [PDF]

Turk J Med Sci
Şener S, Şener YZ, Batu ED, Sari A, Akdoğan A.   +4 more
europepmc   +1 more source